Cytochrome P450 2C9-CYP2C9.
作者信息
Van Booven Derek, Marsh Sharon, McLeod Howard, Carrillo Michelle Whirl, Sangkuhl Katrin, Klein Teri E, Altman Russ B
机构信息
Center for Pharmacogenomics at Washington University, St Louis, Missouri, USA.
出版信息
Pharmacogenet Genomics. 2010 Apr;20(4):277-81. doi: 10.1097/FPC.0b013e3283349e84.
Abstract
摘要
相似文献
1
Cytochrome P450 2C9-CYP2C9.细胞色素P450 2C9 - CYP2C9
Pharmacogenet Genomics. 2010 Apr;20(4):277-81. doi: 10.1097/FPC.0b013e3283349e84.
2
Association between the CYP2C9 polymorphism and the drug metabolism phenotype.细胞色素P450 2C9基因多态性与药物代谢表型之间的关联。
Clin Chem Lab Med. 2004 Jan;42(1):72-8. doi: 10.1515/CCLM.2004.014.
3
Genetic polymorphism of the human cytochrome P450 2C9 gene and its clinical significance.人类细胞色素 P450 2C9 基因的遗传多态性及其临床意义。
Curr Drug Metab. 2009 Sep;10(7):781-834. doi: 10.2174/138920009789895480.
4
Genetic polymorphism of CYP2C9 in a Vietnamese Kinh population.越南京族人群中CYP2C9的基因多态性
Ther Drug Monit. 2005 Apr;27(2):208-10. doi: 10.1097/01.ftd.0000153402.91854.42.
5
Distribution of the major cytochrome P450 (CYP) 2C9 genetic variants in a Saudi population.沙特人群中主要细胞色素 P450（CYP）2C9 遗传变异的分布。
Basic Clin Pharmacol Toxicol. 2011 Aug;109(2):111-4. doi: 10.1111/j.1742-7843.2011.00692.x. Epub 2011 Mar 28.
6
Catalytic activities of human cytochrome P450 2C9*1, 2C9*3 and 2C9*13.人细胞色素P450 2C9*1、2C9*3和2C9*13的催化活性。
Xenobiotica. 2005 Sep;35(9):853-61. doi: 10.1080/00498250500256367.
7
Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development.人细胞色素P450 2C9的底物、诱导剂、抑制剂及构效关系及其在药物开发中的意义
Curr Med Chem. 2009;16(27):3480-675. doi: 10.2174/092986709789057635. Epub 2009 Sep 1.
8
Pharmacogenetics of the cytochromes P450: Selected pharmacological and toxicological aspects.细胞色素P450的药物遗传学：选定的药理学和毒理学方面。
Adv Pharmacol. 2022;95:49-72. doi: 10.1016/bs.apha.2022.05.001. Epub 2022 Jul 20.
9
The risk of myocardial infarction in patients with reduced activity of cytochrome P450 2C9.细胞色素P450 2C9活性降低的患者发生心肌梗死的风险。
Pharmacogenet Genomics. 2007 Jul;17(7):473-9. doi: 10.1097/01.fpc.0000236335.57046.c8.
10
The structure of human cytochrome P450 2C9 complexed with flurbiprofen at 2.0-A resolution.人细胞色素P450 2C9与氟比洛芬复合物在2.0埃分辨率下的结构。
J Biol Chem. 2004 Aug 20;279(34):35630-7. doi: 10.1074/jbc.M405427200. Epub 2004 Jun 4.
引用本文的文献
1
Small-Molecule Trk Agonists: Where Do We Go from Here?小分子Trk激动剂：我们将何去何从？
J Med Chem. 2025 Aug 14;68(15):15233-15259. doi: 10.1021/acs.jmedchem.4c02365. Epub 2025 Jul 18.
2
Comparison of new secondgeneration H1 receptor blockers with some molecules; a study involving DFT, molecular docking, ADMET, biological target and activity.新型第二代H1受体阻滞剂与某些分子的比较；一项涉及密度泛函理论（DFT）、分子对接、药物代谢动力学（ADMET）、生物靶点及活性的研究。
BMC Chem. 2025 Jan 4;19(1):4. doi: 10.1186/s13065-024-01371-4.
3
Ethnic Aspects of Valproic Acid P-Oxidation.丙戊酸P-氧化的种族因素
Biomedicines. 2024 May 8;12(5):1036. doi: 10.3390/biomedicines12051036.
4
Pharmacogenetic Variation in Neanderthals and Denisovans and Implications for Human Health and Response to Medications.尼安德特人和丹尼索瓦人的药物遗传学变异及其对人类健康和药物反应的影响。
Genome Biol Evol. 2023 Dec 1;15(12). doi: 10.1093/gbe/evad222.
5
A Comprehensive Review on Chemistry and Biology of Tafamidis in Transthyretin Amyloidosis.标题：转甲状腺素蛋白淀粉样变性症中塔法米迪的化学和生物学的全面综述
Mini Rev Med Chem. 2024;24(6):571-587. doi: 10.2174/0113895575241556231003055323.
6
Characterization of pharmacogenomic variants in a Brazilian admixed cohort of elderly individuals based on whole-genome sequencing data.基于全基因组测序数据对巴西老年混合队列中的药物基因组变异进行特征分析。
Front Pharmacol. 2023 May 10;14:1178715. doi: 10.3389/fphar.2023.1178715. eCollection 2023.
7
Cannabis Pharmacogenomics: A Path to Personalized Medicine.大麻药物基因组学：通往个性化医疗之路。
Curr Issues Mol Biol. 2023 Apr 17;45(4):3479-3514. doi: 10.3390/cimb45040228.
8
Healthcare Disparities and Upper Gastrointestinal Bleeding: Exploring the Linkages.医疗保健差异与上消化道出血：探索两者之间的联系
Cureus. 2023 Apr 22;15(4):e37977. doi: 10.7759/cureus.37977. eCollection 2023 Apr.
9
Pharmacogenomic and Statistical Analysis.药物基因组学与统计分析
Methods Mol Biol. 2023;2629:305-330. doi: 10.1007/978-1-0716-2986-4_14.
10
Global distribution of functionally important CYP2C9 alleles and their inferred metabolic consequences.具有重要功能的 CYP2C9 等位基因的全球分布及其推断的代谢后果。
Hum Genomics. 2023 Feb 28;17(1):15. doi: 10.1186/s40246-023-00461-z.
本文引用的文献
1
Global variation in CYP2C8-CYP2C9 functional haplotypes.CYP2C8 - CYP2C9功能单倍型的全球变异。
Pharmacogenomics J. 2009 Aug;9(4):283-90. doi: 10.1038/tpj.2009.10. Epub 2009 Apr 21.
2
Relative impact of genotype and enzyme induction on the metabolic capacity of CYP2C9 in healthy volunteers.基因型和酶诱导对健康志愿者中CYP2C9代谢能力的相对影响。
Clin Pharmacol Ther. 2009 Jul;86(1):54-61. doi: 10.1038/clpt.2009.40. Epub 2009 Apr 15.
3
CYP2C9 amino acid residues influencing phenytoin turnover and metabolite regio- and stereochemistry.影响苯妥英代谢周转以及代谢物区域化学和立体化学的CYP2C9氨基酸残基。
J Pharmacol Exp Ther. 2009 Jun;329(3):938-44. doi: 10.1124/jpet.109.150706. Epub 2009 Mar 3.
4
Cytochrome P450 2C9 variants influence response to celecoxib for prevention of colorectal adenoma.细胞色素P450 2C9基因变异影响塞来昔布预防结直肠腺瘤的疗效。
Gastroenterology. 2009 Jun;136(7):2127-2136.e1. doi: 10.1053/j.gastro.2009.02.045. Epub 2009 Feb 21.
5
CYP2C9 polymorphisms: considerations in NSAID therapy.CYP2C9基因多态性：非甾体抗炎药治疗中的考量因素
Curr Opin Drug Discov Devel. 2009 Jan;12(1):108-14.
6
Pharmacogenetic variation at CYP2C9, CYP2C19, and CYP2D6 at global and microgeographic scales.全球及微观地理尺度下CYP2C9、CYP2C19和CYP2D6的药物遗传学变异。
Pharmacogenet Genomics. 2009 Feb;19(2):170-9. doi: 10.1097/FPC.0b013e32831ebb30.
7
Prediction of the effects of genetic polymorphism on the pharmacokinetics of CYP2C9 substrates from in vitro data.根据体外数据预测基因多态性对CYP2C9底物药代动力学的影响。
Pharm Res. 2009 Apr;26(4):822-35. doi: 10.1007/s11095-008-9781-2. Epub 2008 Dec 12.
8
Influence of CYP2C9 genotype on warfarin dose requirements--a systematic review and meta-analysis.CYP2C9基因分型对华法林剂量需求的影响——一项系统评价与荟萃分析
Eur J Clin Pharmacol. 2009 Apr;65(4):365-75. doi: 10.1007/s00228-008-0584-5. Epub 2008 Nov 25.
9
Cytochrome P450 induction by rifampicin in healthy subjects: determination using the Karolinska cocktail and the endogenous CYP3A4 marker 4beta-hydroxycholesterol.利福平对健康受试者细胞色素P450的诱导作用：使用卡罗林斯卡鸡尾酒法和内源性CYP3A4标志物4β-羟基胆固醇进行测定
Clin Pharmacol Ther. 2008 Nov;84(5):589-94. doi: 10.1038/clpt.2008.132. Epub 2008 Jul 23.
10
Influence of polymorphisms of drug metabolizing enzymes (CYP2B6, CYP2C9, CYP2C19, CYP3A4, CYP3A5, GSTA1, GSTP1, ALDH1A1 and ALDH3A1) on the pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide.药物代谢酶（CYP2B6、CYP2C9、CYP2C19、CYP3A4、CYP3A5、GSTA1、GSTP1、ALDH1A1和ALDH3A1）多态性对环磷酰胺和4-羟基环磷酰胺药代动力学的影响。
Pharmacogenet Genomics. 2008 Jun;18(6):515-23. doi: 10.1097/FPC.0b013e3282fc9766.
Zotero 插件